NCT04895202View on ClinicalTrials.gov

Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study

TerminatedOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

November 19, 2021

Primary Completion Date

December 20, 2022

Study Completion Date

December 20, 2022

Conditions
Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions
OTHER

Siponimod

Prospective observational cohort study. There is no treatment allocation. Patients administered siponimod as by swiss label, that have started before inclusion of the patient into the study will be enrolled.

Trial Locations (6)

3010

Novartis Investigative Site, Bern

4031

Novartis Investigative Site, Basel

6300

Novartis Investigative Site, Zug

6900

Novartis Investigative Site, Lugano

8006

Novartis Investigative Site, Zurich

8400

Novartis Investigative Site, Winterthur

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY